Arthneeti
IL

Ipca Laboratories Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Ipca Laboratories Q2 Results 2026 (FY27): Guides 10–20% Revenue Growth, Margins Up

Q2 FY27 earnings call: what management said on revenue, margins and capex.

Revenue
₹2,910Cr
Net profit
₹389Cr
Margin
23.1%

What the Q2 FY27 call signalled

1 of 2 strong

RevenueModerate growth
MarginMargins slightly up
Price₹1,950
Market cap₹49.5K Cr
P/E36.0

The short version

Ipca's branded pain segment, including Zerodol, is growing at 14-16% with expectations to sustain similar growth for the next 3-4 years. Ipca Laboratories expects a consolidated EBITDA margin improvement of around 1% to 1.25% annually over the next 2-3 years.

From Ipca Laboratories Ltd's Q2 FY27 earnings-call transcript · updated 6 Nov 2026.

How did Ipca Laboratories' revenue grow in the September 2026 quarter?

Moderate growth
  • Ipca's branded pain segment, including Zerodol, is growing at 14-16% with expectations to sustain similar growth for the next 3-4 years.
  • Volume-led growth in pain segment is around 8-9%, with price growth at 4-4.5%.
  • Overall, the company expects to maintain 15-16% growth in branded business in India.
  • Export formulation business grew 32% in Q2 FY '27, indicating strong growth momentum.
  • Generic markets (excluding tender) showed 36% growth in Q2 FY '27.
  • U.S. portfolio growth: Ipca portfolio grew 74% in dollar terms, overall U.S. business up 31%.
  • Europe and Australia businesses grew 23-24%; South Africa and Canada grew 45-46%.

2 more points from Ipca Laboratories Ltd's call on revenue

Create a free account to keep reading this call

What happened to Ipca Laboratories' margins in Q2 FY27?

See what Ipca Laboratories Ltd said on profitability & margins — free account, 30 seconds.

What capex is Ipca Laboratories planning?

The management primarily discusses financial results, business segment growth, debt status, subsidiary performance, and margin outlook without detailing capital expenditure or strategic investment initiatives. Therefore, based on the available content: - No direct references to current or future capex or capital investments were made. - Focus remained on operational performance, debt status, and business growth metrics. For detailed capital investment plans, one may need to refer to official company disclosures or future earnings calls or reports.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Ipca Laboratories raising money or cutting debt?

See what Ipca Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Ipca Laboratories' order book?

  • The order book for the institutional business is currently strong with good positions, particularly in the API segment.
  • One subsidiary, Pisgah, is expected to improve by next financial year due to good order positions on the API side.
  • The company expects overall institutional business sales to be around INR 325-340 crores for the full year, slightly above the earlier INR 300 crore guidance, partly due to shipments deferred from last year.
  • The business remains conservative on guidance for institutional segment due to its lumpy nature.

Ipca Laboratories Ltd — Quarterly revenue & net profit

Revenue Net profit
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27

Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the table below.

Ipca Laboratories Ltd Q2 FY27 results — key figures

Ipca Laboratories Ltd Q2 FY27 reported results vs year-ago quarter, ₹ crore
₹ CrQ2 FY27
Revenue2,910
Operating profit (EBITDA)673
Operating margin23.1%
Profit before tax547
Net profit (PAT)389
EPS (₹)14.79

Source: Ipca Laboratories Ltd's results filing to NSE (consolidated), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹2.8K Cr, net profit ₹424 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Ipca Laboratories's management said in earlier quarters

Earlier calls (8)

Others in Pharmaceuticals & Biotechnology this season

  • Gland Pharma Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹18,336 million, a 23% YoY increase from ₹14,869 million in Q2 FY26 (Page 5). Key investor presentation takeaways from Gland Ph

  • OneSource Specialty Pharma (Q2 FY27)

    . Key concall takeaways from OneSource Specialty Pharma Ltd's Q2 FY27 earnings call — and how it ranks against sector peers.

  • Supriya Lifescience (Q2 FY27)

    Q2 FY27 revenue from operations: INR 2,063.0 Mn, a 3.2% YoY increase from INR 1,998.3 Mn in Q2 FY26 (Page 9). Key investor presentation takeaways from Supriya L

  • Sai Life Sciences Ltd (Q2 FY27)

    Revenue for Q2 FY27: ₹659 Cr, a 23% year-on-year (YoY) growth from ₹537 Cr in Q2 FY26 (Page 8, 30). Key investor presentation takeaways from Sai Life Sciences L

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Ipca Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Ipca Laboratories Ltd Q2 FY27 results?

Ipca's branded pain segment, including Zerodol, is growing at 14-16% with expectations to sustain similar growth for the next 3-4 years. Ipca Laboratories expects a consolidated EBITDA margin improvement of around 1% to 1.25% annually over the next 2-3 years.

What is Ipca Laboratories Ltd share price analysis?

Ipca Laboratories Ltd currently shows a below-average growth signal. The stock trades at a P/E of 36.0 with a market cap of ₹49,451 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Ipca Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.